Seminars in Hematology
Volume 40, Issue 1 , Pages 87-96 , January 2003

Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia

References 

  1. Aguayo A, Kantarjian H, Manshouri T, et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245
  2. Algar EM, Khromykh T, Smith SI, et al.  A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene. 1996;12:1005–1014
  3. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000;11:355–360
  4. Andersen MH, Pedersen L, Becker JC, et al.  Identification of a cytotoxic response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869–872
  5. Andersen MH, Pedersen L, Capeller B, et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964–5968
  6. Azuma T, Makita M, Ninomiya K, et al.  Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol. 2002;116:601–603
  7. Baird PN, Simmons PJ. Expression of Wilms' tumor gene (WT1) in normal hematopoiesis. Exp Hematol. 1997;25:312–320
  8. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  9. Ben-Neriah Y, Daley GQ, Mes-Massan AM, et al.  The chronic myelogenous leukemia-specific P210 protein the product of the bcr/abl hybrid gene. Science. 1986;233:212–214
  10. Berke Z, Andersen MH, Pederson M, et al.  Peptides spanning the junctional region of both the abl/bcr and bcr-abl fusion proteins bind common HLA class I molecules. Leukemia. 2000;14:419–426
  11. Blagosklonny MV, Fojo T, Bhalla KN, et al.  The heat shock protein 90 antagonist geldanamycin selectively sensitizes Bcr-Abl expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 2001;15:1537–1543
  12. Bocchia M, Korontsvit T, Xu Q, et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587–3592
  13. Bocchia M, Wentworth PA, Southwood S, et al.  Specific binding of leukemia oncogene fusion protein peptide to HLA class I molecules. Blood. 1995;85:2680–2684
  14. Brossart P, Spahlinger B, Grunebach F, et al.  Induction of minor histocompatibility antigen HA-1 specific cytotoxic T lymphocytes for the treatment of leukemia after allogeneic stem cell transplantation. Blood. 1999;94:4374–4376
  15. Buzyn A, Ostankovitch M, Zerbib A, et al.  Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol. 1997;27:2066–2072
  16. Carter BZ, Milella M, Altieri DC, et al.  Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001;97:2784–2790
  17. Cathcart KN, Pinilla-Ibarz J, Korontsvit T, et al.  T cell immunity to Philadelphia chromosome (Ph1) positive acute lymphocytic leukemia (ALL): p190 bcr-abl breakpoint derived peptides can generate in vitro T cell responses. Blood. 1999;94(suppl 1, abstr 341):78a
  18. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al.  All CML patients vaccinated with a multivalent bcr-abl peptide vaccine show specific immune responses in a phase II trial. Blood. 2001;98(suppl 1, abstr 3038):728a
  19. Chen W, Peace DJ, Rovira DK, et al.  T-cell immunity to the joining region of p210 BCR-ABL protein. Proc Natl Acad Sci USA. 1992;89:1468–1472
  20. Chen W, Quin H, Reese V, et al.  CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J Immunother. 1998;21:257–268
  21. Clark RE, Dodi IA, Hill SC, et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the b3a2 BCR-ABL protein. Blood. 2001;98:2887–2893
  22. Claxton DF, McMannis J, Champlin R, et al.  Therapeutic potential of leukemia-derived dendritic cells: Preclinical and clinical progress. Crit Rev Immunol. 2001;21:147–155
  23. Choudhury A, Gajewski JL, Liang JC, et al.  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133–1142
  24. de Klein A, Geurts van Kessel A, Grosveld G, et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765–767
  25. Den Haan JM, Meadow L, Wang W, et al.  The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054–1057
  26. Den Haan JM, Sherman NE, Blokland E, et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995;268:1476–1480
  27. Dickinson AM, Wang XN, Sviland L. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410–414
  28. Druker BJ, Sawyers CI, Kantarjian H, et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  29. Elisseeva OA, Oka Y, Tsuboi A, et al.  Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002;99:3272–3279
  30. Engels FH, Koski Gk, Bedrosian I, et al.  Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci USA. 1999;96:10332–10337
  31. Faber LM, Vanluxemburg-Heijs SA, Willemze R, et al.  Generation of leukemia reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176:1283–1289
  32. Falkenberg JH, Goselink HM, Harst Van der D, et al.  Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med. 1991;174:27–33
  33. Falkenburg JH, Wafelman AR, Joosten P, et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia reactive cytotoxic T lymphocytes. Blood. 1999;94:1201–1208
  34. Ferrarini M, Heltai S, Zocchi MR, et al.  Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer. 1992;51:613–619
  35. Fontaine P, Roy-Proulx G, Knafo L. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med. 2001;7:789–794
  36. Fujii S, Shimizu K, Fujimoto K, et al.  Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 1999;90:1117–1129
  37. Gaiger A, Carter L, Greinix H, et al.  WT1-specific antibodies in patients with leukemia. Clin Cancer Res. 2001;7:761s–765s
  38. Gao L, Bellantuono I, Alsasser A, et al.  Selective elimination of leukemia CD34(+) progenitor cells by cytotoxic T lymphocyte specific for WT1. Blood. 2000;95:2198–2203
  39. Greco G, Fruci D, Accapezzato D, et al.  Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia. 1996;10:693–699
  40. Grosveld G, van Agthoven T, de Klein A, et al.  The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr-abl transcript. Mol Cell Biol. 1986;6:607–616
  41. He L, Feng H, Raymond A, et al.  Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl positive leukemia in mice. Cancer Immunol Immunother. 2001;50:31–40
  42. Heinzinger M, Waller CF, Von Der Berg A, et al.  Generation of dendritic cells from patients with chronic myeloid leukemia. Ann Hematol. 1999;78:181–186
  43. Heisterkamp N, Stephenson JR, Groffen J, et al.  Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature. 1983;306:239–242
  44. Inoue K, Ogawa H, Yamagami T, et al.  Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene). Blood. 1996;88:2267–2278
  45. Kantarjian H, Sawyers C, Hochhaus A, et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  46. Kloetzer W, Kurzrock R, Smith L, et al.  The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has associated tyrosinase protein kinase activity. Virology. 1985;140:230–238
  47. Lim SH, Coleman S, Bailey-Wood R. In vitro cytokine-primed leukemia cells induce in vivo T cell responsiveness in chronic myeloid leukemia. Bone Marrow Transplant. 1998;22:1185–1190
  48. Lundberg LG, Lerner R, Sundelin P, et al.  Bone marrow in polycythemia vera, CML, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15–19
  49. Mannering SI, McKenzie JL, Fearnley DB, et al.  HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen presenting cells exposed to b3a2 containing cell lysates. Blood. 1997;90:290–297
  50. Maurer U, Brieger J, Weidman E, et al.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol. 1997;25:945–950
  51. Menssen HD, Renkl HJ, Rodeck U, et al.  Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemia. Leukemia. 1995;9:1060–1067
  52. Miwa H, Beran M, Saunders GF, et al.  Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia. 1992;6:405–409
  53. Miyagi T, Ahuja H, Kubota T, et al.  Expression of the candidate Wilms' tumor gene (WT1) in human leukemia cells. Leukemia. 1993;7:970–977
  54. Molldrem JJ, Clave E, Jiang YZ, et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony forming units. Blood. 1997;90:2529–2534
  55. Molldrem J, Dermine S, Parker K, et al.  Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 peptide preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450–2457
  56. Molldrem JJ, Lee P, Wang C, et al.  A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59:2675–2681
  57. Molldrem JJ, Lee P, Wang C, et al.  Evidence that specific T-lymphocytes may participate in the elimination of chronic myeloid leukemia. Nat Med. 2000;6:1018–1023
  58. Mori A, Wada H, Nishimura Y, et al.  Expression of the antiapoptotic gene survivin in human leukemia. Int J Hematol. 2002;75:161–165
  59. Muller L, Provenzani C, Faul C, et al.  Recognition of chronic myelogenous leukemia cells by autologous T lymphocytes primed in vitro against the patient dendritic cells. Br J Haematol. 2001;112:740–748
  60. Mutis T, Verdijk R, Schrama E, et al.  Feasibility of immunotherapy of relapsed leukaemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system–restricted minor histocompatibility antigens. Blood. 1999;93:2336–2341
  61. Neckers L. Hsp inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8:S55–S61
  62. Nieda M, Nicol A, Kikuchi A, et al.  Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. Blood. 1998;91:977–983
  63. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allyamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl positive human leukemic blasts. Cancer Res. 2001;61:1799–1804
  64. Norbury lC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol. 2000;109:616–621
  65. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497–1501
  66. Ohminami H, Yasukawa M, Fugita S. HLA class I restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286–293
  67. Oka Y, Elisseeva OA, Tsuboi A, et al.  Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99–107
  68. Oka Y, Udaka K, Tsuboi A, et al.  Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 2000;164:1873–1880
  69. Osman Y, Takahashi M, Zheng Z, et al.  Generation of bcr-abl specific cytotoxicity T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia. 1999;13:166–174
  70. Pawelec G, Max H, Halder T, et al.  BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood. 1996;88:2118–2124
  71. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al.  Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781–1787
  72. Ratajczak MZ, Ratajczak J, Machalinski B, et al.  Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth. Br J Haematol. 1998;103:969–979
  73. Rowley JD: A. new consistent chromosomal abnormality in chronic myelogenous leukaemia, identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293 (letter)
  74. Schmitz M, Diestelkoetter P, Weigle B, et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000;60:4845–4849
  75. Shiotsu Y, Neckers LM, Wortman I, et al.  Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood. 2000;96:2284–2291
  76. Shtivelman E, Lifshitz B, Gale RP, et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–554
  77. Smit WM, Rijnbeek M, Van Bergen CA, et al.  Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. 1997;53:216–223
  78. Smit WM, Rijnbeek M, Van Bergen CA, et al.  T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA. 1998;95:10152–10157
  79. Tanaka Y, Takahashi T, Nieda M, et al.  Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. Br J Haematol. 2000;109:435–437
  80. Tanaka Y, Takahashi T, Nieda M, et al.  Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide. Leuk Res. 2002;26:317–321
  81. ten Bosch GJA, Joosten AM, Kessler JH, et al.  Recognition of BCR-ABL positive leukemic blast by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996;9:3522–3527
  82. ten Bosch GJA, Kessler JH, Joosten AM, et al.  A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Iib2a2 construct. Blood. 1999;94:1038–1045
  83. ten Bosch GJ, Toornvliet AC, et al.  Recognition of peptides corresponding to the joining region of p210 bcr-abl protein by human T cells. Leukemia. 1995;9:1344–1348
  84. Tsuboi A, Oka Y, Ogawa H, et al.  Cytotoxic T lymphocyte response elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol. 2000;20:195–202
  85. Verstovsek S, Kantajian H, Manshouri T, et al.  Prognostic significance of cellular vascular endothelial growth factor expression on chronic phase chronic myeloid leukemia. Blood. 2002;99:2265–2267
  86. Warren E, Gavin M, Simpson E, et al.  The human UTY gene encodes a novel HLA B8-restricted H-Y antigen. J Immunol. 2000;164:2807–2814
  87. Warren E, Greenberg P, Riddle S. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197–2207
  88. Westermann J, Kopp J, Korner I, et al.  BCR/ABL positive dendritic cells for vaccination in chronic myeloid leukemia. Bone Marrow Transplant. 2000;25:S46–S49
  89. Westermann J, Richter G, Kopp J, et al.  Dendritic cells for vaccination in bcr/abl positive chronic myeloid leukemia. Blood. 1999;94(suppl 2, abstr 4470):281b
  90. Wieder ED, Kant S, Lu S, et al.  Effective specific immunity induced after PR1 peptide vaccination correlates with cytogenetic remission. Blood. 2001;98(suppl 1, abstr 1708):407a
  91. Yamagami T, Sugiyama H, Inoue K, et al.  Growth inhibition of human leukemia cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotide implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878–2884
  92. Yang XF, Wu CJ, Chen LY, et al.  CML28 is a broadly immunogenic tumor antigen associated with immune-induced remission of chronic myelogenous leukemia. Blood. 2001;98(suppl 1, abstr 3037):728a
  93. Yang XF, Wu CJ, Mclaughlin S, et al.  CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 2001;98:7492–7497
  94. Yasukawa M. Immunotherapy for leukemia targeting the Wilms' tumor gene. Leukemia and Lymphoma. 2001;42:267–273
  95. Yasukawa M, Ohminami H, Kaneko S, et al.  CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion protein augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood. 1998;92:2361–3355
  96. Yasukawa M, Ohminami H, Kojima K, et al.  HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. Blood. 2001;98:1498–1505
  97. Yotnda P, Firat H, Garcia-Pons F, et al.  Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998;101:2290–2296
  98. Zorn E, Orsini E, Wu CJ, et al.  A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes bcr-abl breakpoint peptides but not tumor cells. Transplantation. 2001;7:1131–1137

☆ D.A.S. is a Doris Duke Distinguished Clinical Scientist. J.S. is a Lauri Strauss Leukemia Foundation Fellow.

☆☆ Address reprint requests to David A. Scheinberg, MD, PhD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 531, New York, NY 10021.

PII: S0037-1963(03)70046-8

Seminars in Hematology
Volume 40, Issue 1 , Pages 87-96 , January 2003

Article Tools